RU2690841C1 - Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества - Google Patents

Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества Download PDF

Info

Publication number
RU2690841C1
RU2690841C1 RU2016119132A RU2016119132A RU2690841C1 RU 2690841 C1 RU2690841 C1 RU 2690841C1 RU 2016119132 A RU2016119132 A RU 2016119132A RU 2016119132 A RU2016119132 A RU 2016119132A RU 2690841 C1 RU2690841 C1 RU 2690841C1
Authority
RU
Russia
Prior art keywords
implant
biodegradable
eye
months
biodegradable implant
Prior art date
Application number
RU2016119132A
Other languages
English (en)
Russian (ru)
Other versions
RU2016119132A (ru
Inventor
Джейн-Гуо ШИА
Рауль БАГАТ
Венди М. БЛАНДА
Тьерри НИВАГЖИОЛИ
Линь ПЭН
Дэвид ЧОУ
Дэвид А. ВЕБЕР
Original Assignee
Аллерган, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52001114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2690841(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аллерган, Инк. filed Critical Аллерган, Инк.
Publication of RU2016119132A publication Critical patent/RU2016119132A/ru
Application granted granted Critical
Publication of RU2690841C1 publication Critical patent/RU2690841C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
RU2016119132A 2013-11-15 2014-11-14 Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества RU2690841C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361904887P 2013-11-15 2013-11-15
US61/904,887 2013-11-15
PCT/US2014/065804 WO2015073895A1 (en) 2013-11-15 2014-11-14 Methods of treatment of ocular conditions with a sustained drug delivery implant

Publications (2)

Publication Number Publication Date
RU2016119132A RU2016119132A (ru) 2017-12-20
RU2690841C1 true RU2690841C1 (ru) 2019-06-06

Family

ID=52001114

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016119132A RU2690841C1 (ru) 2013-11-15 2014-11-14 Способы лечения патологических состояний глаза с помощью имплантата с долговременной доставкой лекарственного вещества

Country Status (24)

Country Link
US (2) US20150140062A1 (enExample)
EP (2) EP3714875A1 (enExample)
JP (2) JP6675307B2 (enExample)
KR (3) KR20220082934A (enExample)
CN (1) CN105764517A (enExample)
AU (4) AU2014348369B2 (enExample)
CA (1) CA2929689A1 (enExample)
CL (1) CL2016001167A1 (enExample)
CY (1) CY1123344T1 (enExample)
DK (1) DK3068403T3 (enExample)
ES (1) ES2819215T5 (enExample)
HU (1) HUE050913T2 (enExample)
IL (2) IL245548A0 (enExample)
MX (2) MX2016006334A (enExample)
MY (1) MY176039A (enExample)
NZ (1) NZ719953A (enExample)
PH (1) PH12016500869B1 (enExample)
PL (1) PL3068403T3 (enExample)
PT (1) PT3068403T (enExample)
RU (1) RU2690841C1 (enExample)
SG (1) SG10201809363SA (enExample)
SI (1) SI3068403T1 (enExample)
UA (1) UA122117C2 (enExample)
WO (1) WO2015073895A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115337254A (zh) * 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
AU2017321980B2 (en) 2016-09-02 2020-04-30 Alcon Inc. Implant applicators
CA3087238A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS
CN111989068B (zh) 2018-05-24 2024-10-25 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CN116133664A (zh) * 2020-07-16 2023-05-16 视觉治疗股份有限公司 含有糖皮质激素的眼部插入物
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2389479C2 (ru) * 2004-08-13 2010-05-20 Аллерган, Инк. Глазной имплантат, изготавливаемый способом двойной экструзии

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
AU2012214146A1 (en) * 2011-02-11 2013-08-29 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2389479C2 (ru) * 2004-08-13 2010-05-20 Аллерган, Инк. Глазной имплантат, изготавливаемый способом двойной экструзии

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAM M BOYD, M.D. CROSS-DISCIPLINE TEAM LEADER REVIEW, NDA 22-315, OZURDEX (dexamethasone intravitreal implant)/CENTER FOR DRUG EVALUATION AND RESEARCH, 17.06.2009 (URL:http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022315s000_CrossR.pdf). *

Also Published As

Publication number Publication date
CA2929689A1 (en) 2015-05-21
US20250319031A1 (en) 2025-10-16
JP2016538292A (ja) 2016-12-08
CL2016001167A1 (es) 2017-01-06
AU2024205640A1 (en) 2024-08-29
DK3068403T3 (da) 2020-09-07
SI3068403T1 (sl) 2020-11-30
KR102475746B1 (ko) 2022-12-08
ES2819215T5 (en) 2026-04-01
KR20220082934A (ko) 2022-06-17
US20150140062A1 (en) 2015-05-21
CN105764517A (zh) 2016-07-13
RU2016119132A (ru) 2017-12-20
CY1123344T1 (el) 2021-12-31
IL245548A0 (en) 2016-06-30
PH12016500869A1 (en) 2016-07-04
JP7022735B2 (ja) 2022-02-18
KR20240058976A (ko) 2024-05-07
NZ719953A (en) 2022-01-28
PL3068403T3 (pl) 2021-01-11
AU2014348369A1 (en) 2016-06-09
MY176039A (en) 2020-07-22
UA122117C2 (uk) 2020-09-25
AU2024205640B2 (en) 2025-10-23
JP2020055862A (ja) 2020-04-09
ES2819215T3 (es) 2021-04-15
IL290837A (en) 2022-04-01
AU2020204362A1 (en) 2020-07-23
WO2015073895A1 (en) 2015-05-21
HUE050913T2 (hu) 2021-01-28
JP6675307B2 (ja) 2020-04-01
EP3068403B1 (en) 2020-06-17
KR20160085847A (ko) 2016-07-18
PT3068403T (pt) 2020-09-18
AU2022204607A1 (en) 2022-07-21
MX2022002306A (es) 2022-03-25
AU2014348369B2 (en) 2020-04-02
MX2016006334A (es) 2016-09-06
SG10201809363SA (en) 2018-11-29
EP3714875A1 (en) 2020-09-30
PH12016500869B1 (en) 2016-07-04
EP3068403A1 (en) 2016-09-21
EP3068403B2 (en) 2025-12-03

Similar Documents

Publication Publication Date Title
AU2024205640B2 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
Gaballa et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives
US20230172948A1 (en) Ocular implant made by a double extrusion proces
JP6132964B2 (ja) 萎縮性加齢性黄斑変性の処置方法
Sun et al. Episcleral drug film for better-targeted ocular drug delivery and controlled release using multilayered poly-ε-caprolactone (PCL)
Lee et al. Novel drug delivery systems for retinal diseases: a review
US20150272877A1 (en) Ketorolac-containing sustained release drug delivery systems
Shin et al. Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis
Yilmaz et al. Triamcinolone and intraocular sustained-release delivery systems in diabetic retinopathy
Kulkarni et al. Corticosteroid therapies in the management of macular edema secondary to retinal vein occlusion
HK40038783A (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770B (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
HK1228770A1 (en) Methods of treatment of ocular conditions with a sustained drug delivery implant
Relhan et al. Intraocular sustained-release steroids for uveitis
Ahuja et al. Post-operative assesment of single subconjunctival triamcinolone acetate injection vs topical corticosteroid in cataract surgery: A prospective control study
Ahmed et al. A comparative study between foldable Iris Claw Lens and ICL (Implantable Collamer Lens) Phakic IOLs in correcting moderate and high Myopia
WO2024226533A1 (en) Methods for treating ocular disorders with integrin antagonist composition
Augustin et al. Suprachoroidal drug delivery–a new approach for the treatment of severe macular diseases
Kreissig et al. Diffuse diabetic macular edema: results after intravitreal triamcinolone acetonide